Monte Rosa Therapeutics, Inc. Revenue from Contract with Customer, Including Assessed Tax
Monte Rosa Therapeutics, Inc. (GLUE) reported Revenue from Contract with Customer, Including Assessed Tax of $8.97 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $8.97M, a 61.33% decline year-over-year.
- Monte Rosa Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $4.21M, a 95.04% decline year-over-year.
- Monte Rosa Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $2.78M, a 95.41% decline year-over-year.
- Monte Rosa Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $12.77M, a 38.54% increase year-over-year.
- Monte Rosa Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2025 was $123.67M, a 63.54% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2024 was $75.62M.
- Monte Rosa Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2023 was $0.00.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.97M 10-Q · filed 2026-08-06 | $13.18M 10-Q · filed 2026-08-06 | $15.96M derived: sum of 3 quarters · filed 2026-08-06 | $28.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.21M 10-Q · filed 2026-05-07 | $6.99M derived: sum of 2 quarters · filed 2026-05-07 | $19.76M derived: sum of 3 quarters · filed 2026-05-07 | $42.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $15.55M derived: sum of 2 quarters · filed 2026-03-17 | $38.74M derived: sum of 3 quarters · filed 2026-08-06 | $123.67M 10-K · filed 2026-03-17 |
| 2025-09-30 | $12.77M 10-Q · filed 2025-11-06 | $35.96M derived: sum of 2 quarters · filed 2026-08-06 | $120.89M 10-Q · filed 2025-11-06 | $181.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $23.19M 10-Q · filed 2026-08-06 | $108.12M 10-Q · filed 2026-08-06 | $168.77M derived: sum of 3 quarters · filed 2026-08-06 | $177.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $84.93M 10-Q · filed 2026-05-07 | $145.58M derived: sum of 2 quarters · filed 2026-05-07 | $154.79M derived: sum of 3 quarters · filed 2026-05-07 | $159.49M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $60.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $69.86M derived: sum of 2 quarters · filed 2026-03-17 | $74.56M derived: sum of 3 quarters · filed 2026-03-17 | $75.62M 10-K · filed 2026-03-17 |
| 2024-09-30 | $9.22M 10-Q · filed 2025-11-06 | $13.91M derived: sum of 2 quarters · filed 2025-11-06 | $14.97M 10-Q · filed 2025-11-06 | $14.97M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $4.70M 10-Q · filed 2025-08-07 | $5.76M 10-Q · filed 2025-08-07 | $5.76M derived: sum of 3 quarters · filed 2025-08-07 | $5.76M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.06M 10-Q · filed 2025-05-08 | $1.06M derived: sum of 2 quarters · filed 2025-05-08 | $1.06M derived: sum of 3 quarters · filed 2025-05-08 | $1.06M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $0.00 derived: sum of 3 quarters · filed 2025-03-20 | $0.00 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |